Please login to the form below

Not currently logged in

talimogene laherparepvec

This page shows the latest talimogene laherparepvec news and features for those working in and with pharma, biotech and healthcare.

Boehringer buys into oncolytic viruses via €210m ViraTherapeutics deal

Boehringer buys into oncolytic viruses via €210m ViraTherapeutics deal

This form of immuno-oncology has been spearheaded by Amgen, whose Imlygic (talimogene laherparepvec or T-Vec) was approved by the FDA last year, although it was not the first oncolytic

Latest news

More from news
Approximately 4 fully matching, plus 16 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Nitro Digital

Nitro Digital is an award-winning full service digital marketing agency focused on the life science sector. We offer a strategic...

Latest intelligence

Revisiting Instagram for pharma
In pharma, Instagram usage is increasing because it offers so many benefits to engage with patients and HCPs...
The one multichannel question you must ask
There is a question every marketer should ask when designing a multichannel communications strategy...
Medius Deal Watch
Deal Watch September 2016
Abbott, Allergan, Celgene, Moderna, Pfizer and Takeda feature in this month's pharma deals round-up...